Gossamer Bio
Identification of novel inhibitor(s) targeting NLRP3 inflammasome activation
About
The Gossamer Thread
Management
Board of Directors
Pipeline
Pipeline Overview
Posters and Publications
Patients
Patients Overview
Expanded Access Policy
News
Get In Touch
Locations
Contact Us
Sponsorship Disclosures
Work at Gossamer
our benefits
career opportunities
Identification of novel inhibitor(s) targeting NLRP3 inflammasome activation
CYT – September 2022
Now Enrolling: The PROSERA Phase 3 study of seralutinib in adults with Pulmonary Arterial Hypertension (PAH).
PROSERA clinical trial: NCT05934526
Learn more about the study
MENU
The Gossamer Thread
Management
Board of Directors
Investors
overview
news
events/presentations
events
presentations
filings
governance
overview
committee composition
board of directors
management
stock
stock quote & chart
analyst coverage
info
faqs
contact ir
email alerts
Pipeline
Pipeline Overview
Posters and Publications
Patients
Patients Overview
Expanded Access Policy
News
Get In Touch
Locations
Contact Us
Sponsorship Disclosures
Work at Gossamer
our benefits
career opportunities
Follow Us
